PMID: 9419346Feb 21, 1998Paper

Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells

Proceedings of the National Academy of Sciences of the United States of America
D S SiegelJ Michaeli

Abstract

Multiple myeloma (MM) is a B cell malignancy characterized by the expansion of monoclonal Ig-secreting plasma cells with low proliferative activity. It is postulated that inhibition of physiologic cell death is an underlying factor in the pathophysiology of MM. The development of chemoresistance is a common feature in patients with MM. In the present studies, hexamethylene bisacetamide (HMBA), a hybrid polar compound that is a potent inducer of terminal differentiation of various transformed cells, is shown to inhibit the growth of several human myeloma cell lines (ARP-1, U266, and RPMI 8226), including doxorubicin-resistant RPMI 8226 variants that overexpress the multidrug-resistance gene, MDR-1, and its product, p-glycoprotein. In addition to growth arrest and suppression of clonogenicity, HMBA induces apoptosis both in freshly isolated human myeloma cells and in cell lines, as determined by morphologic alterations, cell cycle distribution and endonucleosomal DNA fragmentation. Further, HMBA decreases BCL-2 protein expression in myeloma cells within 12-48 hr. Overexpression of BCL-2 protein in ARP-1 cells confers resistance to HMBA-induced apoptosis. Taken together, these data suggest that HMBA is a potent inducer of apoptosi...Continue Reading

References

Nov 1, 1992·The Journal of Cell Biology·Y GavrieliS A Ben-Sasson
Jun 28, 1991·Cell·G T Williams
May 1, 1995·Cellular Immunology·A LichtensteinJ Berenson
Dec 11, 1994·Nucleic Acids Research·M HerrmannJ R Kalden
Oct 25, 1994·Proceedings of the National Academy of Sciences of the United States of America·P A MarksR A Rifkind
Mar 1, 1993·Blood Reviews·R NiesvizkyJ Michaeli
Apr 1, 1994·Environmental Science & Technology

❮ Previous
Next ❯

Citations

Oct 21, 1999·Journal of Cellular Physiology·L Miele, B Osborne
Jul 13, 2001·Cell Biology International·N V ShirsatA Mehta
Nov 16, 2004·Cancer Chemotherapy and Pharmacology·Camilla PalumboAndrea Modesti
Apr 10, 1999·Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie·P A MarksR A Rifkind
Nov 10, 2009·Journal of the American Chemical Society·Christer B AakeröyJohn Desper
Oct 8, 2011·Natural Product Reports·Subash C GuptaBharat B Aggarwal
Jan 13, 2009·The Journal of Biological Chemistry·Xavier ContrerasB Matija Peterlin
Jan 23, 1999·Current Opinion in Oncology·M L Varterasian
Aug 24, 2010·Journal of Experimental & Clinical Cancer Research : CR·Xingguo ZhongRenhua Gong
Mar 16, 2001·Breast Cancer Research : BCR·T K SaidD Medina
Oct 17, 2007·PLoS Pathogens·Xavier ContrerasB Matija Peterlin
Sep 28, 2000·Biochemical and Biophysical Research Communications·K M TaintonR W Johnstone
Jan 22, 2004·Proceedings of the National Academy of Sciences of the United States of America·C-Y GuiP A Marks
Apr 18, 1998·Proceedings of the National Academy of Sciences of the United States of America·V M RichonP A Marks
Aug 15, 2003·Leukemia & Lymphoma·Quan ChenAlexandru Almasan
Mar 23, 2013·Viruses·Ran Taube, Matija Peterlin
Oct 30, 2007·Leukemia Research·V CecchinatoR Chiaramonte
Mar 27, 2007·The International Journal of Biochemistry & Cell Biology·Holger Hess-StumppOliver Politz
Jul 13, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Yeonghwan KimSung-Soo Kim
Feb 21, 2004·Biochemical and Biophysical Research Communications·Eunyoung Chun, Ki-Young Lee
Apr 12, 2005·European Journal of Cell Biology·Holger Hess-Stumpp
Jun 2, 2015·Acta Pharmacologica Sinica·Hong-tao ShangFu-jun Liang
May 16, 2000·Leukemia & Lymphoma·R W JohnstoneM J Smyth
Dec 2, 2006·Chembiochem : a European Journal of Chemical Biology·Zhichao ZhangFengyu Liu
Feb 26, 2000·BJU International·A F Badawi
Apr 19, 2003·The Journal of Biological Chemistry·Annamaria BevilacquaAngelo Nicolin
Dec 10, 1999·British Journal of Pharmacology·N MaricicB M Peskar
Dec 8, 2009·Medicinal Research Reviews·Mohammed Naseer A Khan, Yong Sup Lee
Dec 21, 2016·British Journal of Sports Medicine·Robert James ThomasAlfonso Jimenez
Mar 31, 2004·World Journal of Gastroenterology : WJG·Gao-Liang OuyangShi-Deng Bao
Oct 11, 2001·Oncogene·A CalastrettiA Nicolin

❮ Previous
Next ❯

Related Concepts

Related Feeds

B cell Differentiation

Depending on the signal received through the B cell receptor and other receptors, B cells differentiate into follicular or marginal zone B cells. Here is the latest research pertaining to this differentiation process.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.